Consent given pursuant to Sections 14 and 14A to the supply of the therapeutic goods specified by Reckitt Benckiser Australia

Overview

The Therapeutic Goods Act 1989 was enacted to regulate the quality, efficacy, and safety of therapeutic goods in Australia, including medicines, medical devices, and other related products. This Act was introduced to address the need for a comprehensive framework to ensure that therapeutic goods available in the Australian market meet the necessary standards for public health and safety. Enacted by the Australian Parliament, the policy objective of the Act is to protect public health by ensuring that therapeutic goods are of acceptable quality, perform as claimed, and do not pose unacceptable risks to consumers when used as intended. This legislative measure enables the Therapeutic Goods Administration to manage and control the supply, advertising, and distribution of therapeutic goods, thereby safeguarding the health and well-being of Australians.

Scope and Application

The Therapeutic Goods Act 1989 (TGA) applies to the regulation of therapeutic goods in Australia, ensuring that these products are of acceptable quality, safety, and efficacy. The Act governs the approval, manufacturing, advertising, and supply of therapeutic goods, which include medicines, medical devices, and other health-related products. It applies to entities such as manufacturers, importers, sponsors, and suppliers who engage in activities related to the supply of therapeutic goods within Australia. The Act's reach extends to all states and territories within the Commonwealth, providing a unified regulatory framework. While the Act provides for broad application, certain therapeutic goods may be exempt or subject to specific conditions, such as those outlined in therapeutic goods orders or other subordinate legislation. The Act also allows for the issuance of consents, such as the one provided for the specified batches and pack sizes of certain medicinal products, which temporarily exempts them from certain labelling requirements pending legislative updates. This consent is strictly conditional and temporal, applying only until 31 August 2016, and is subject to compliance with the previously approved labels by the Therapeutic Goods Administration (TGA).

Key Provisions

Sections 14 and 14A of the Therapeutic Goods Act 1989 (the Act) pertain to the supply of therapeutic goods that do not conform to the standards set by the Therapeutic Goods Administration (TGA). Under these sections, the delegate of the Secretary of the Department of Health has the authority to consent to such supply if it is in the public interest. In this case, the consent was granted to Reckitt Benckiser Australia Pty Ltd for specific batches of their products, which do not yet include all the new warning statements required by an upcoming legislative instrument. This consent allows for the continued supply of these products until the labels are updated to comply with the new requirements. The obligations imposed by the Act on entities such as Reckitt Benckiser Australia Pty Ltd include ensuring that their products conform to the standards and requirements set by the TGA. In this instance, the company must ensure that their labels include all mandated warning statements by 12 December 2015. The consent granted under sections 14 and 14A requires adherence to specific conditions, including the use of previously approved labels until the required updates are made. Failure to comply with the provisions of the Therapeutic Goods Act 1989 can result in various civil and criminal consequences. Offences under the Act can include supplying non-compliant therapeutic goods, which may result in fines and penalties. The maximum penalty for contravening certain provisions of the Act can be substantial, including fines up to $1.65 million for corporations and up to $330,000 for individuals, depending on the severity and intent of the breach. Additionally, individuals found guilty of serious offences may face imprisonment. The Act provides a framework for enforcement to ensure that therapeutic goods supplied in Australia meet safety, quality, and efficacy standards.